samarth kulkarni family

Learn More on Samarth Kulkarni's age. Dr Hemant Kulkarni is our family physician since so many years and for any of our health issues our first call is to him.We are family of 4 and all members take his . Family rooms . Mira has an extensive collection of sarees including her favourite Banarasi saree that her grandmother gave her. Yes. Founders & Scientific Advisors. The estimated net worth of Samarth Kulkarni is at least $19 Million dollars as of 2023-02-16. And I think the 120 CR rates are -- seem to be higher, right; I think or BCMA, in general. All rights reserved. Learn More about Samarth Kulkarni's net worth. And I think, you know, the allogeneic therapies can always improve it overtime. We have the RMAT designation in the U.S. which gives us the ability to have frequent dialogue with regulators in the U.S. and PRIME designation in Europe which also gives the same ability to speak with the EMEA folks quite regularly. Estee Lauders first investment in India was with Forest Essentials. I think -- but we always want to be looking at other diseases as well, we don't want to become a purely oncology player. An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Samarth (Sam) Kulkarni, Ph.D. currently serves as CEO of CRISPR Therapeutics AG. Can you maybe just give us a quick overview of that program, how you're viewing it? Mira Kulkarni was born in 1958(age 64 years; as of 2022) in Tehri Garhwal, Uttarakhand. Learn More about insider trades at CRISPR Therapeutics. The West Whiteland Township man found shot dead alongside his wife and two sons on Sunday had purchased a gun two weeks before police found the family's bodies in the basement of their home, law enforcement sources said Wednesday. You know, obviously with EHA coming up next week and the data update in sickle cell and beta thal; maybe provide just a little bit of context on what to expect in terms of data updates, obviously, you've provided updates in enrollment recently in trial. How are you thinking about the oncology program? Your email address will not be published. She was the best outgoing student during her post graduation course. After returning to India, Kulkarni got involved in a cooperative movement in Rishikesh (Uttarakhand) that focused on marketing handmade products. Save my name, email, and website in this browser for the next time I comment. Discover the immediate steps you need to take now. After graduating in B.Tech in Biotechnology from IIT Kharagpur, he received a Ph.D in bioengineering and nanotechnology from the University of Washington. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief Business Officer before becoming CEO. Your email address will not be published. Divya works as the creative director of Forest Essentials. Fast. And how enrollment has proceeded since the data update at ASH last year? CBS News Reports: "It's an entirely new type of weapon." And now there is this notion like in re-dose, preemptively, as a consolidation dose, and that's the way to get durability because you've completely eliminated the cancer. Again, we want to do a controlled experiment. And if you can see that -- if you can see that these cells indeed are capable of sensing glucose and producing insulin, that is a -- that takes meaningful risk off the table. She realised that Rishikesh could be an ideal location where she could start her business as it is an ayurvedic, wellness hub and home to hundreds of ayurvedic doctors and there are pharmacies that sell homemade soaps, oils, lotions, creams, and other products. If we need to, we'll go that route of the GSIs but at this point, we're trying to work with the original hypothesis which is that beta-2-M gives us that persistence; it won't be overwhelmed by the soluble BCMA, and -- but we still see responses. And what we've learned is that, as a year ago, there were probably two schools of thought; there is like this notion that you're going to re-dose every time you progress, and that's how you're going to ensure durability. And so we're learning more about CAR-Ts in general, and we're also learning more about allogeneic versus autologous therapies, and the same sort of metrics and lenses that you apply to autologous may not apply to allogeneic. Dr. News Karnataka 2012 - 2023 All Rights Reserved by, Vijayapura: Samarth Kulkarni, a blooming cricketing talent. Training and Placement Student Coordinator at Sandip Foundation. Eventually, I think allogeneic therapies will get it better than autologous therapies, even with the high bar that's set. Swami Samarth Maharaj Temple - 200 meter (2 minute walking distance) Swami Samarth Samadhi - 1 km; Bhuikot Fort (Solapur) - 38 km; Distances from Akkalkot. Please use this link for your account He also serves on the Board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO). Now, I think the rest of the world and Asia is a different story. Yes. Yes, absolutely. Mira mentioned in one of her interviews that at the beginning of her business, she used to casually give away her self-made ayurvedic handmade soaps to friends and family. Samarth has made over 30 trades of the CRISPR Therapeutics AG stock since 2017, according to the Form 4 filled with the SEC. No credit card required. Mira was 28 years old when her parents passed away. CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology . Dr. Samarth Kulkarni has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. Thanks, Sam, for joining us. And as far as, you know, how -- the medium to expect the data from those programs; you've had some where you've done, obviously, in concert with a medical meeting, some you've done with a webcast event, press release. Yes, that's helpful. And I talked with autologous BCMA programs which is better than some of the other programs out there today. Log in or sign up for Facebook to connect with friends, family and people you know. or. And so far we're continuing the trial, there is a lot of interest in the program, we're dose escalating as we go along; and we look forward to providing updates. It almost took Kulkarni and her team two years to come up with their first product. Learn More about Samarth Kulkarni's net worth. It was so not fashionable to use the hand-ground ubtan biji and not to use anything else to wash your face. We haven't activated that because we want to see how it plays. But again, I think we need to be -- have a sense of activity that's close to what the benchmark is, for us to Tinker and Taylor, right. Are goalscorers born or made? He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. 927 Sq. CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. So, maybe just to set the stage for our discussion, you could maybe provide just a quick overview of the pipeline, as it stands today, and maybe just a few of the upcoming catalysts that investors can expect in '21. This led to the companys expansion. CRISPR Therapeutics AG has a market cap of $10.49 billion; its shares were traded at around $148.410000 with and P/S ratio of 129.60. PLC programmer at Danfoss Power Solutions. In an interview, Kulkarni revealed that she always carries a cashmere shawl, a small music dock, a notepad, an iPad, scented bath oil, perfume, and a Tejasvi Emulsion during her travels. And then, with the most recent deal with the negotiations over the 10%, and the control of the launch, how you were thinking about it from CRISPR's perspective? Beyond that, we have a very rich pipeline. Responsible for troubleshooting and maintaining existing Lab test stands for pumps and motors. Learn More on Samarth Kulkarni's salary. Dr. Kulkarni owns 369,111 shares of CRISPR Therapeutics stock worth more than $17,724,710 as of February 25th. A. Ghalge and P. Bhattacharyya, Information Extraction from Indo Aryan Family of Natural Languages Using a Rule . Mira got married at the age of nineteen. Copyright 2023, THG PUBLISHING PVT LTD. or its affiliated companies. In the past Samarth Kulkarni held the position of Partner at McKinsey & Co., Inc. He has authored several publications in leading scientific and business journals. | Property ID - 11356048. A decade after the CRISPR Cas9 platform was elucidated and developed by Dr. Emmanuelle Charpentier and Dr. Jennifer Doudna; we're very pleased to be at the forefront of leveraging this exciting platform for groundbreaking therapies in a very short amount of time as a company. Most recently he exercised 25,000 units of CRSP stock worth $421,000 on 26 October 2022. . Shillong (Meghalaya) - Violence erupted in three Constituencies after the results of the Assembly Elections in Meghalaya were declared. You have some wiggle room; we got some latitude. And I think, for us with our allo-therapies, especially with the CD70 target, we think it's very attractive target given the expression and renal cell carcinoma in a highly immunologic cancer, I think it gives us that opportunity. Because I think -- why is that? We are led by a seasoned management team, an experienced board of directors and accomplished scientific founders with extensive experience across the biotechnology and pharmaceutical industries. . In the last year, insiders at the sold shares 9 times. But I think, you know, in this market, time is an important component; I think it's going to be difficult for -- for players to get a commercial foothold, if there has been a player existing already for four or five years with very good data, right. 1 BHK Apartment for Sale in Maval, Lonavala. So I think -- we look forward to providing continued updates as we go along at this conference and next. Warning! With our oncology programs, we have three different CAR-Ts. CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced. The Hindu Centre for Politics and Public Policy, Supreme Court forms expert panel to probe any regulatory failure on Adani issue, China says border should be kept in proper place, calls for resuming direct flights with India, India makes renewed push for consensus at G20 Foreign Ministers meeting, Seeping saffron: On the BJP and their partners electoral gains in the northeast, Searing changes: On heatwaves predicted by the Met Office, Sun Pharma reports information security incident, Embassy Group sells 4% stake in Embassy REIT to Bain Capital, 1947: Madras Devadasis (Prevention of Dedication) Act passed, World Test Championship points table update: India drops PCT, Australia qualifies for WTC final with Indore win; qualification scenarios. She prefers wearing cotton, khadi, linen and pure silk sarees. Yes, I think this would be huge. The price of the stock has increased by 18.73% since. And especially, with the data that came out from legend yesterday, I think you're looking at a 2-in-3 types CR rate. I think you saw something yesterday in the news around ICANS with autologous therapies, but you may not necessarily see that with allogeneic therapies, even if you have the same potency of killing, right. Thanks for that. Dr. Samarth Kulkarni has served as our Chief Executive Officer since 2017. In the letter, she wrote. Find your friends on Facebook. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. I mean, obviously, a little early, but an important question on the direction of the company. Yes. Right. Later, he met Mira and picked up a 20% stake in Forest Essentials. Great. Get all the latest news and updates on Bollywood, Hollywood, South India film industry, cinemas in India, film stars, celebrities, movie reviews and much more at outlookindia.com. While at the University of Washington, Sam conducted research on the delivery of biological drugs and in the field of molecular diagnostics. Russia's war on Ukraine latest: Putin casts war as battle for nation's survival, India FM Jaishankar says Soros dangerous, debate needed on democracy, Buffett's Berkshire profit falls on investments, currencies, Bill Gates buys Heineken stake, despite saying he's 'not a big beer drinker', Elon Musk recruits team to develop OpenAI rival - The Information, Hedge fund manager Chris Hohn demands Airbus drop Atos deal - letter, Elon Musk's challenge: Stay ahead of the competition, ISS urges Apple shareholders to vote for CEO Tim Cook, other execs' pay packages, Elon Musk accuses media of racism after newspapers drop 'Dilbert' cartoon, French media billionaire Niel fails with bid for TNT television frequence - Arcom, Transcript : CRISPR Therapeutics AG Presents at Citi's 2023 Virtual Oncology Leadership Summit, Feb-22-2023 01:00 PM, Transcript : CRISPR Therapeutics AG Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-18-2023 10:30 AM, Transcript : CRISPR Therapeutics AG Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 11:40 AM, Chief Executive Officer & Executive Director. And what are the relative kinetics of it, what are the relative dynamics of it in terms of tumor volume reduction and amount of doses you need, etcetera. , 2+ . Save my name, email, and website in this browser for the next time I comment. So let's say, you have a program with 55% CR rate, relative to 65% CR rate; there is 10% delta. Samarth Kulkarni is Chairman of Casebia Therapeutics LLP. document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() ); Mira Kulkarni Wiki, Age, Husband, Children, Family, Biography & More, Ashok Elluswamy Wiki, Age, Girlfriend, Wife, Family, Biography & More, Asish Mohapatra Wiki, Age, Wife, Family, Biography & More, Nithin Kamath Wiki, Age, Girlfriend, Wife, Children, Family, Biography & More, Mahhaguru Dr. Gauravv Mittal Wiki, Age, Family, Biography & More, Fahim Saleh Wiki, Age, Death, Girlfriend, Wife, Family, Biography & More, Anmol Ambani Wiki, Height, Age, Wife, Family, Biography & More, Anita Dongre Wiki, Age, Boyfriend, Husband, Family, Biography & More, Romil Ramgarhia Wiki, Age, Family, Biography & More, N. R. Narayana Murthy Wiki, Age, Wife, Children, Family, Biography & More, Sunny Kapoor Wiki, Age, Wife, Family, Biography & More, Lee Watson (Shane Watsons Wife) Wiki, Age,, Akshata Murthy Wiki, Age, Boyfriend, Husband, Family,, Kumar Mangalam Birla Wiki, Age, Wife, Children,, Akshat Shrivastava Wiki, Age, Wife, Family, Biography, J.R.D. Information on this page was last updated on 2/27/2023. Now, all that said, I think, you know, as we look at the data from our -- for ourselves versus other companies, there are many different ways to look at our data; you know, eventually when we disclose the data, you'll have a basis for comparison. I think -- I do think that eventually, there is other constructs coming out where you're turbocharging with cytokines or making other edits. Post-poll violence that erupted in at least three assembly constituencies in Meghalaya left several people injured. from the Indian Institute of Technology. This chart shows Samarth Kulkarni's buying and selling at CRISPR Therapeutics by year and by quarter. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief Business Officer before becoming CEO. You will also learn to prioritise and do things that are important to you, and learn that everyone cannot do everything. How do we come up with improvements in process and analytical capabilities to that so that we can further streamline that patient experience and improve outcomes for patients? I think every patient so far has been free of symptoms as you compare that to lentiviral approaches, you know, the data look better, and when you combine that with the fact that CRISPR is a notionally safer approach relative to random integration of lentivirus, I think you'll have a huge advantage in the marketplace. And if -- you know, in the original construct, we had CRISPR as the commercializing party for the U.S. with Vertex for ex-U.S. And that's -- that would be ideal if you can do that because then there is no argument really for doing autologous therapies. In Bengaluru, Samarth started playing for the Social Cricket Club, where he made a remarkable impression on the coaches. Samarth Kulkarni "Sam" Chief Executive Officer . Sayali Ghodekar, Pushpak Bhattacharyya, Gholamreza Haffari and Malhar Kulkarni, Cognition-aware Cognate Detection, 16th . Dr. Samarth Kulkarni has served as our Chief Executive Officer since 2017. Yes. So I think while it's -- you know, won't be difficult for people to enroll patients because there is a lot of demand for gene editing in sickle cell and thalassemia, I think commercially, we are well positioned to take on that leadership mantle and maintain it overtime. And subsequently what we've disclosed is that we've dosed more patients in our EHA abstract, there is a greater number of patients, we have 14 patients; 10 thalassemia, 4 sickle cell patients. Learn More on Samarth Kulkarni's trading history. The company has almost 80 stores in India,and it supplies its products to 190 hotels and exports them to 120 countries. So, I think it aligns capabilities well, the capital does make a difference for us as we further expand the rest of our pipeline. And with that, it's a pleasure to have Sam Kulkarni, the CEO of CRISPR Therapeutics with us for this fireside chats. You are at risk for having your bank account frozen. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief Business Officer before becoming CEO. CRISPR Therapeutics AG is a gene editing company. If you have an ad-blocker enabled you may be blocked from proceeding. Samarth Kulkarni is Chairman of Casebia Therapeutics LLP. He has served as the companys Chief Business Officer and president before being promoted as CEO. Mira got married at the age of nineteen. But if you look at all the venture capital activity, all the places where money is going into, it's regenerative medicine, for a good reason. Yes. He joined CRISPR in the early He then along with Gastroenterologist and Surgeon (Dr . A spacious house for your family, this unit includes 1 bedroom. [BREAKING] New "Living Missile" to Replace Nuclear Missiles. Prashant has been working with Samarth on the basic level of his game and giving valuable tips to improve his performance. And most of all, I think it makes sense for patients suffering from sickle cell disease and thalassemia because this is the best chance of making sure that this program gets wide access to all these patients that need and deserve the therapy. You know, this is a question on the oncology platform and the company commercialization strategy as a whole. He had an exceptional performance in the recent South Zone matches held in Kerala in January 2023, where he got an opportunity to play in only 4 matches and took 17 wickets. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. from the Indian Institute of Technology. CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), and Michael Tomsicek (CFO). With oncology, how we play in the long run is isn't -- it's a question that we evaluate every so often. And I think, you know, just looking at it from a capability standpoint, it made sense to align the capabilities in a way where you can leverage all of what Vertex have to this globally coordinated launch, and bring their best practices to bear from cystic fibrosis in other markets to ensure that we can reach as many patients as we can. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before . While at the University of Washington, he conducted research on the delivery of biological drugs and in the field of molecular diagnostics. And obviously, you touched on this a little bit, but the global manufacturing cohesion that you have, can you maybe just describe a little bit about how that -- how to view that in the context of the rest of the pivotal -- the rest of the current clinical trial, as well, as approaching the agency, just given some things that we've seen in the space recently with regards to regulatory filings with the lentivirus procedure? I think subsequent data releases have been as part of medical conferences, we did that with OO1 [ph]. Dr. Samarth Kulkarni has served as our Chief Executive Officer since 2017. He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. But we continue to make progress in that program to get that program to patients in a widely accessible manner through -- by getting to filing an approval. He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. I believe that consistent performance in junior level cricket, support of my parents and encouragement of my coaches will surely help me in achieving my dreams, he said. Learn More on CRISPR Therapeutics' active insiders. They cannot be abusive or personal. But we'll provide guidance as we go along throughout the year, as to when to expect the data. I think those are all things that will be important to compare contrast as we go along, but it's less about us versus another company in allogeneic, it's more about allogeneic versus other modalities. Biden To Unleash "Choke Point" Operation On America? Learn more here: bit.ly/3vMwJxG. It made sense to have a coordinated launch, you know, to have one company lead it, whether it's CRISPR or Vertex. Following the completion of the sale, the chief executive officer now directly owns 375,988 shares of the company's stock, valued at $18,141,421. View profile badges. If you do not have an account please register and login to post comments. And then maybe after the ASH data, if you could provide any color on how physicians are looking at the data set to date? He has authored several publications in leading scientific and business journals. An example electronic device includes a chassis including a first cover and a second . An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Samarth (Sam) Kulkarni, Ph.D. currently serves as CEO of CRISPR Therapeutics AG. Users can access their older comments by logging into their accounts on Vuukle. Dr. Kulkarni earned a salary of $670,000.00, stock awards of $4,819,680.00, options awards of $10,954,947.00, non-equity compensation of $587,925.00, and other compensation of $4,463.00. Dr. Rodger Novak, M.D., co-founder and current Chief Executive Officer of CRISPR Therapeutics, is stepping down from his current role for personal reasons but will continue to serve as a member of the Company's board of directors and as an officer of its Swiss parent company, CRISPR AG. The price of the stock has decreased by 3.96% since. So, I think -- I think that combined with the fact that the regulators are quite closely in touch across the U.S. and Europe, it gives us that ability to sort of advance this as one global trial, ultimately, with the notion that the filing package would be similar or same across U.S. and Europe. It allows us to play across different business models; the business models would be different for other diseases versus oncology but I think as one single entity, we do get synergies by playing across both. You know, I think we used to get a lot of questions of CRS and ICANs; I think that's [indiscernible] understand that that may be more of an autologous phenomenon than allogeneic because you just don't have the same kind of expansion. I mean, how are you looking at your 120 update in the context of autologous? While at McKinsey, he co-led the biotech practice, where he focused on strategy and operations, and led initiatives in areas such as personalized medicine and immunotherapy. As the CEO of CRISPR Therapeutics AG, Dr. Kulkarni earned a total compensation package of $17,037,015.00 in 2021. So maybe can you just talk about how the Vertex collaboration started? But at least at this point, that plan seems to hold true. Commissioning new test stands. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. And though no official ruling has been issued by county investigators, the early indication . In 2016, Mira received the Vogue India Beauty Award for her immense contribution to the Beauty Industry. This was revealed after a tweet from Dr. Kulkarni was shared widely among Belagavi residents with congratulatory messages and tags about his schooling in the city. And again, I think the company has done an amazing job with bringing very -- relatively recent scientific breakthrough into real clinical results; I think that's kudos to you and the team at CRISPR. All contact info about Samarth Kulkarni, 44 from Boston, Massachusetts - address, e-mail, phone, public records, etc at PublicReports FOR FREE In about six years we've gone from starting with a platform -- research platform to having multiple candidates in the clinic. She did her schooling at Loreto Convent, Tara Hall, Shimla. Learn More on Samarth Kulkarni's trading history. Neumnster, Schleswig-Holstein, Germany. We have migrated to a new commenting platform. Never listen to someone who tells you that what you want to do is not possible. Tech. But in this context, as you look at the data, the trials are global; we're looking at the market in a way that there is a lot of shared responsibilities from a central global marketing, I would say, versus regional. So that was seen as big -- sort of proof-of-concept point. You should be as comfortable in your orange rubber slippers as you are in your new staggeringly-high Louboutins. You know, maybe just provide a little bit of color on how you're viewing CTX001 in the context of the clinical development landscape, obviously, a bunch of different modalities looking at HbH 87Q [ph], HbF and HbG [ph], for example. So I think there is tremendous potential in regenerative medicine, which I don't think everybody is catching on to at this point; we essentially get very little value I think ascribed to us right now in pre-gen med. I think we -- our pancreas are banana shaped organ that we're -- but only a small portion of that is actually catering towards glucose homeostasis. They sold a total of 225,000 shares worth more than $12,961,000.00. Some good, some not so much. I think there are a number of players that are following in our footsteps. Kulkarni will assume the role effective December 1, 2017. Sam currently serves on the Board of Directors of two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics. I think everyone was looking at the program very differently and saying, gosh, this can be a huge advance in the field of medicine. Drafted Notices, Replies to Notices, etc. Developing new software and simulation models of the test stands for virtual commissioning. Lakshmikumaran and Sridharan. Learn to delegate, but delegate judiciously, and to competent people. I think you'll have a different way of looking at reimbursement for maybe, you know, Germany versus Italy versus the U.S. And there we have to have a more nuanced and bespoke strategy, but otherwise, I think this notion of global trials makes a lot of sense, it gives us -- it allows us to move faster, and allows us to make sure that we have a very coordinated package. CRISPR Therapeutics AG (NASDAQ:CRSP) William Blair & Company 41st Annual Growth Stock Conference Call June 3, 2021 12:20 PM ET, Samarth Kulkarni - Chief Executive Officer. Chart Data in Insider Trading History Table. Systems, devices, and methods for generating and sending messages are described. Find the best odds at 10Cric and IPL Betting 2023! Samarth Bedi began his career with Standard Chartered Bank in New York in 1999, and in 2001, he joined Forest Essentials as the managing director. Mira Kulkarni owns a Glasshouse named Neemranas Glasshouse, a riverside property with 20 accommodations, which is located on the banks of the Ganges. This week on the For Your Innovation Podcast, we're joined by Dr. Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics. And I think, you know, the -- I'm glad the field is pursuing both of those options to see what's better. Click for complete details on 99acres.com With 120, the BCMA targeted product; I mean, obviously, you know, the response rates are numerically higher with the autologous programs. Dr. Satish G Kulkarni (Samarth Diagnostic) in Vashi, Navi Mumbai, Mumbai is a top player in the category Gastroenterologists in the Navi Mumbai, Mumbai. Later, she pursued graduation in Fine Arts at Stella Maris College, Chennai. Samarths talent in cricket was first recognised when he represented the Karnataka State Under-14 cricket team. Yes, I think ASH last year was a very important milestone for the program. And once you're getting to approval, it's going to move -- it's going to leapfrog autologous therapies, because it's going to move much faster, it's easier to enroll patients in allogeneic therapies versus autologous therapies; imagine trying to expand your autologous cell therapy trials to community settings, just very slow, you're not going to get there.